What is Cognoptix?
Cognoptix is at the forefront of developing a non-invasive beta amyloid eye scanning test designed for the early detection and diagnosis of Alzheimer's Disease. Their proprietary Sapphire II system offers a straightforward eye scan procedure, suitable for clinical settings, addressing a critical need for accessible and accurate diagnostic tools. The company's mission is to enhance cognitive health management through early intervention, empowering both physicians and patients.
How much funding has Cognoptix raised?
Cognoptix has raised a total of $42.1M across 6 funding rounds:
Series A
$1M
Series B
$18.5M
Series C
$4.6M
Debt
$390K
Series D
$15M
Other Financing Round
$2.6M
Series A (2007): $1M, investors not publicly disclosed
Series B (2008): $18.5M led by Inventages
Series C (2011): $4.6M, investors not publicly disclosed
Debt (2014): $390K featuring Inventages
Series D (2014): $15M backed by Launchpad Venture Group LLC, Inventages, and Alopexx
Other Financing Round (2020): $2.6M with participation from Launchpad Venture Group LLC, Harvard Business School Alumni Angels of Greater New York, and New York Angels Inc
Key Investors in Cognoptix
Launchpad Venture Group LLC
Launchpad Venture Group is a network of angel investors focused on providing financial and human capital investments in early-stage tech and science-driven startups based in New England. They seek to build long-term relationships with innovative entrepreneurs and offer mentorship alongside their capital investments.
Inventages
Inventages is one of the world's largest life-sciences, nutrition and wellness focused venture capital fund managers. They add value by supporting portfolio companies with strategy development, assisting in major financial transactions, and recruiting key executives.
Alopexx
Alopexx is a clinical stage biotechnology company focusing on developing novel, broad-spectrum immune-mediated therapeutics for the prevention, treatment and mitigation of a wide range of microbial infections. They are based in Cambridge, Massachusetts.
What's next for Cognoptix?
The recent major enterprise-level funding indicates a pivotal stage for Cognoptix, likely enabling the company to scale its operations, advance clinical trials, and pursue regulatory approvals. This strategic capital infusion is expected to accelerate the commercialization of their diagnostic platform, potentially forming key partnerships with pharmaceutical entities and academic institutions to broaden the reach and impact of their Alzheimer's detection technology. The company's trajectory suggests a strong focus on market penetration and establishing its diagnostic solution as a standard in early cognitive health assessment.
See full Cognoptix company page
